Aeterna Zentaris Settles Dispute with Cogas Consulting, LLC
November 06 2018 - 8:00AM
Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX: AEZS)
and Cogas Consulting, LLC have amicably resolved their dispute with
Aeterna Zentaris Inc. agreeing to make a payment to Cogas
Consulting, LLC in the amount of $625,000. The parties now consider
their contractual relationship as having been terminated for
convenience.
About Aeterna Zentaris Inc.
Aeterna Zentaris Inc. is a specialty biopharmaceutical company
focused on developing and commercializing, principally through
out-licensing arrangements, Macrilen™ (macimorelin), an oral
ghrelin receptor agonist, to be administered in the diagnosis of
patients with adult growth hormone deficiency. Aeterna
Zentaris has entered into a license and assignment agreement with a
wholly-owned subsidiary of Strongbridge Biopharma plc to carry out
development, manufacturing, registration and commercialization of
Macrilen™ (macimorelin) in the United States and Canada. For more
information, visit www.zentaris.com.
Contact:
Leslie AuldChief Financial OfficerAeterna Zentaris
Inc.IR@aezsinc.com843-900-3201
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Sep 2023 to Sep 2024